Results 41 to 50 of about 11,291,129 (270)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Therapeutic Advances in Hematology, 2021
Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface.
Foteini Theodorakakou, Meletios A. Dimopoulos, Efstathios Kastritis   +2 more
doaj   +1 more source

Real‐World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild‐Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records

eJHaem
Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate ...
Muhamed Baljevic, Haechung Chung, Jose Alvir, Patrick Feron, Aaron Crowley, Darrin Benjumea, Yong Chen, Cindi Pankratova   +7 more
doaj   +1 more source

Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study

Cancer Management and Research, 2021
Junhui Xu,* Mangju Wang,* Ye Shen, Miao Yan, Weiwei Xie, Bingjie Wang, Huihui Liu, Xinan Cen Department of Hematology, Peking University First Hospital, Beijing, People’s Republic of China*These authors contributed equally to this ...
Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, Liu H, Cen X   +7 more
doaj  

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker Research, 2023
Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart   +8 more
doaj   +1 more source

Systemic amyloidosis in England: an epidemiological study. [PDF]

, 2013
Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Smith, CJ, Banypersad, SM, Whelan, CJ, Venner, CP, Dungu, J, Pinney, JH, Lachmann, HJ, Taube, JB, Gillmore, JD, Gibbs, SD, Hawkins, PN, Wechalekar, AD   +11 more
core  

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Impact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis

Клиническая онкогематология
AIM. To assess the clinical features as well as the factors affecting prognosis and long-term treatment outcomes in systemic AL amyloidosis patients with cardiac involvement. MATERIALS & METHODS. The trial enrolled 123 systemic AL amyloidosis patients
Olga Vladislavovna Pirogova, O. V. Kudyasheva, M. V. Chernous, M. A. Gorodnova, D. K. Lamden, K. A. Novitskaya, A. G. Smirnova, A. V. Yakovleva, V. A. Ionin, A. M. Ananin, I. S. Moiseev, A. D. Kulagin   +11 more
doaj   +1 more source

Review Article of Cardiac Amyloidosis

Walailak Journal of Science and Technology, 2011
Cardiac amyloidosis is a term that means the deposit of abnormal proteins in the myocardium leading to global thickening of the heart walls. The clinical character is that of infiltrative cardiomyopathy.
Jittiporn PURATTANAMAL
doaj   +1 more source

Hemostasis disorders in patients with systemic AL-amyloidosis

Терапевтический архив, 2023
Aim. To analyze the frequency and nature of hemorrhagic and thrombotic complications in patients with systemic AL-amyloidosis and compare with laboratory changes in the hemostasis system. Materials and methods.
Irina G. Rekhtina, Victoria A. Khyshova, Nadezhda I. Zozulya, Valentina N. Dvirnyk, Larisa P. Mendeleyeva   +4 more
doaj   +1 more source